Psilocybin vs. Nicotine Patch: Johns Hopkins Study Shows Magic Mushrooms Are 6x More Effective for Quitting Smoking

A major breakthrough in psilocybin smoking cessation research is here. If you have ever tried to quit smoking, you know how hard it is. Patches, gums, willpower — most people try many times before they succeed. Now, however, a new study from Johns Hopkins University has changed the game. Researchers found that a single dose of psilocybin — the active compound in magic mushrooms — was six times more effective than the nicotine patch at helping people stay off cigarettes after six months.

Published on March 10, 2026 in JAMA Network Open, one of the most respected medical journals in the world, this is the strongest clinical evidence so far for psilocybin smoking cessation. In this article, we explain what the study found, how psilocybin works differently from traditional methods, and what this could mean for millions of smokers worldwide.

Smoking: Still the World's Biggest Preventable Killer

Before we look at the study, let's talk about why psilocybin smoking cessation research matters so much. According to the World Health Organization, tobacco kills about 8 million people every year. It is still the number one preventable cause of death in the world. Despite decades of anti-smoking campaigns, there are still roughly 1.2 billion smokers on the planet.

Right now, there are seven FDA-approved medications for quitting smoking. Most of them are nicotine replacement products like patches, gums, and lozenges. In addition, there are two prescription drugs: varenicline and bupropion. Even with medication and counseling combined, however, only about 20% to 30% of people manage to stay smoke-free after each attempt. That means 7 out of 10 people go back to smoking every time they try to quit.

As Megan Piper told NPR: "It's been 20 years since we've had a new medication to help people quit smoking. We need something new."

The JAMA Psilocybin Smoking Cessation Trial

The trial took place at Johns Hopkins Bayview Medical Center between 2015 and 2023. In total, 82 healthy adult smokers took part — all of them had tried to quit before and failed at least once. They were randomly split into two groups:

This is important: both groups received the same 13-week program of cognitive behavioral therapy (CBT) for smoking cessation. This means the comparison was fair. Psilocybin was not tested on its own — instead, it was combined with the same therapy the patch group received.

To make sure the results were trustworthy, the researchers did not rely on people simply saying they had quit. Instead, they confirmed it with exhaled carbon monoxide tests and urine cotinine levels. Consequently, there was no guesswork — these were biologically verified results.

Psilocybin Smoking Cessation Results: Six Times Better

After six months, the difference between the two groups was very clear:

In simple terms, the psilocybin group had more than six times the odds of staying smoke-free compared to the patch group. Even among those who did not quit completely, the psilocybin group smoked about 54% fewer cigarettes per day. Therefore, even partial results were much better.

Lead researcher Matthew Johnson, professor of psychiatry at Johns Hopkins, said: "I was surprised by the sheer size of the effect."

How Psilocybin Helps With Smoking Cessation

Here is the most interesting part: psilocybin does not interact with nicotine receptors at all. Traditional methods like patches and gums work by replacing or copying nicotine in your body. As a result, they mainly manage the physical withdrawal. Psilocybin, on the other hand, takes a completely different approach to smoking cessation.

Instead of targeting the chemical addiction, psilocybin seems to work through what researchers call higher-level psychological processes. After you take it, your body converts psilocybin into psilocin. Psilocin then connects to serotonin receptors (especially the 5-HT2A receptor) in the brain. This triggers big changes in how your brain communicates with itself.

Research published in Nature shows that psilocybin increases psychological flexibility — the ability to step out of rigid thinking patterns and see yourself and your habits from a fresh angle. In particular, studies have found that people report big shifts in how they see themselves and what they value. For smokers, this often means breaking free from the identity of "being a smoker" — rather than just fighting the next craving.

Addiction psychiatrist Dr. Brian Barnett from the Cleveland Clinic explained it well: "It's not the drug by itself here. It's really using the brain's ability to rewire and learn after the experience." In addition, Johnson noted that participants often describe how "things get shaken up and they can step outside of that and try something different."

If you want to learn more about how psilocybin works in the brain, we have written about that before. In short, psilocybin allows different brain areas that normally don't talk to each other to suddenly start communicating — like an orchestra finally finding its conductor.

Was the Psilocybin Treatment Safe?

Safety is always a fair question when it comes to psychedelic substances. However, the study reported no serious side effects from either psilocybin or the nicotine patch. Most side effects in the psilocybin group were mild and temporary:

Meanwhile, the nicotine patch group had its own side effects, including skin rashes (18%) and vivid dreams (15%). Depression was reported in both groups at similar rates (30% psilocybin vs. 23% patch), with no meaningful difference between them.

It is important to stress that the psilocybin smoking cessation session took place in a supervised clinical setting. Trained guides were present the entire time. Participants lay in a comfortable room wearing eye shades, listening to soft music, while their vital signs were checked for 8 to 9 hours. If you are curious about what psychedelic experiences feel like at different levels, you can read about the 5 trip levels and how to handle difficult experiences.

Limitations of the Study

No study is perfect, and the researchers were honest about the weak points. First of all, the study was "unblinded." This means both the participants and the researchers knew who received psilocybin. Because the psychedelic experience is so intense, it is nearly impossible to hide which group someone is in. However, this also means that expectations could have played a role in the results.

Furthermore, the group was fairly small (82 participants) and not very diverse — 89% of participants were White and 63% had at least a bachelor's degree. In addition, 65% said they had used psychedelics before, which is much higher than the general population (about 14%). Although extra analysis showed no link between past psychedelic use and outcomes, larger and more diverse studies are clearly needed.

Finally, the psilocybin group spent more time with the research team (about 30 hours vs. 17 hours for the patch group). This was mainly because of the long psilocybin session itself. Future studies will need to account for this difference in contact time.

Even so, the researchers concluded that psilocybin is a "promising candidate for smoking cessation that should move forward in the FDA approval process." A larger follow-up trial funded by the National Institutes of Health — this time with a placebo group — is already underway.

Why Psilocybin Smoking Cessation Matters Beyond This Study

This finding does not stand alone. Psilocybin research has been growing fast across many areas. For instance, a recent Yale University study showed that a single dose of psilocybin can relieve OCD symptoms for months. Similarly, studies on psilocybin for depression, end-of-life anxiety, and alcohol dependence have all shown encouraging results.

The smoking study supports what scientists call a "general anti-addiction effect" of classic psychedelics. In other words, psilocybin does not just help with one specific substance. Instead, it seems to help people break free from rigid behaviour patterns across the board. Consequently, this has big implications for how we think about addiction treatment in general.

At the same time, researchers at the American Chemical Society are also working on non-hallucinogenic psilocin compounds — substances that could deliver the healing benefits of psilocybin without the intense psychedelic experience. One compound, called "4e," showed promising early results: it reached the brain effectively, released psilocin more slowly, and produced far fewer psychedelic effects in animal tests. Although this research is still in its early stages, it could one day make psilocybin-based treatments available to many more people.

The Bigger Picture for Mushroom Science

We have been following psilocybin research since we started this shop in 2009. Honestly, we have never seen a year quite like this one. From the JAMA psilocybin smoking cessation study to the OCD trial, the science is moving faster than ever.

For those of you who are interested in the biology of these remarkable fungi, we keep sharing what we learn. Whether it is how light and tryptamine control psilocybin levels, why spores don't contain psilocybin, or the many reasons people are drawn to magic mushrooms — we believe understanding always comes first.

For now, the message is clear: psilocybin science is no longer on the margins. It is being published in the world's top medical journals, funded by national health institutes, and taken seriously by addiction specialists. For the 1.2 billion smokers around the world, that should feel like a reason for hope.